Equity inducement grants of this size are standard practice and have no trading implications. Investors should focus on upcoming Phase 3 data for azetukalner in epilepsy and the MDD/BPD programs as key catalysts.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $60.96entry
- T+1 · 4mo ago −0.69%α −1.56% · $60.54
- T+5 · 4mo ago +16.40%α +15.47% · $70.96
- T+20 · 4mo ago +5.30%α +5.71% · $64.19
- T+60 · 7w ago −39.76%α −43.33% · $36.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equity awards under Nasdaq Rule 5635(c)(4), with an exercise price of $60.30 per share. The grants are routine retention tools for new hires and have negligible dilutive impact relative to the company's $5.8B market capitalization.
Key Facts
- Aggregate grants: 20,200 share options and 11,850 RSUs to four new non-officer employees
- Option exercise price: $60.30 per share, equal to July 1, 2026 closing price
- Options vest 25% at one-year anniversary, then monthly over 4 years; RSUs vest 25% annually over 4 years
- Grants approved by Compensation Committee as inducements material to employment per Nasdaq Rule 5635(c)(4)
Financial Impact
Total potential dilution of ~32,050 shares, representing approximately 0.05% of outstanding shares, immaterial
Risk Factors
- No material risk, grants are routine and insignificant to valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321547 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Viewing Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers